This workshop on Oct 9th. had been cancelled due to the Government Shutdown and will be rescheduled at a later date.
With Fall approaching, everyone is preparing for their favorite things whether that’s football season, pumpkin carving, or more reasonable temperatures in Central Maryland. Fall is also a great time for the Small Business Innovation Research grant program throughout National Institutes of Health. In partnership with the NIH, BioHealth Innovation is sponsoring a fall gathering to talk about SBIR awards.
It’s useful to hear directly from NIH program officials on the current funding priorities per Institute. We have assembled program leads from NHLBI, NIAID, and NCI who can provide small businesses with more insight into their SBIR programs. They will also be available for one-on-one consultations at the conclusion of the event.
BioMarker Strategies announced the appointment of Jerry Parrott as President, Chief Executive Officer and Director, effective immediately.
According to a release, Parrott will report to the Company’s Board of Directors, which will continue to be led by Chairman Jack Davis, a co-founder and former Chairman and CEO of Dianon Systems.
GlycoMimetics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. GlycoMimetics has applied to list its common stock on the NASDAQ Global Market under the ticker symbol “GLYC.”
Jefferies LLC and Barclays Capital Inc. are acting as joint book-running managers for the proposed offering. Stifel is acting as co-lead manager and Canaccord Genuity Inc. is acting as co-manager.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by email at Prospectus_Department@Jefferies.com or by phone at 877-547-6340 or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at Barclaysprospectus@broadridge.com or by phone at 888-603-5847.
Fyodor, a Baltimore-based biotechnology company, announced today that the US National Science Foundation (NSF) has awarded the company a Small Business Innovation Research (SBIR) Phase 2 grant. The $729,000 funding will help accelerate Fyodor’s effort to develop and validate a noninvasive multi-disease urine-based diagnostic test for Acute Febrile Illness (AFI), enabling the differential clinical diagnosis of leading global health diseases like malaria, typhoid, dengue, and leptospirosis from a single urine specimen in patients with fever.
Berlin, Germany, and U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, announced today that it has entered into a joint commercialization agreement with Polymedco Inc., a leading provider of colorectal cancer tests in North America. Both companies will jointly commercialize Epi proColon®, Epigenomics’ blood-based test for colorectal cancer (CRC) screening, in North America.
Chevy Chase-based New Enterprise Associates has joined in a $10 million financing for Cydan LLC, a Cambridge, Mass.-based orphan drug accelerator.
The additional funding comes months after the project’s launch in April, and brings its total financing to $26 million. Lundbeckfond Ventures and Bay City Capital led the most recent financing.
As health systems and hospitals consolidate and battle for patients, they are starting to employ online consumer marketing efforts. A new Provider Web Presence Index is now available to track the success of providers.
Payer+Provider Syndicate has created the Provider Web Presence Index, which was released Tuesday, and evaluates the quality of the web presence of hospitals compared with competitors. The tool is based on a single indicator, which incorporates measures of web traffic, inbound linking and site relevance.
These days, having a strategic investor or partner has become almost a matter of survival for healthcare startups.
Corporate investing and partnering has really taken off over the last few years as pharma and medical device companies have opened their doors and wallets to find innovation outside of their four walls.
The University of Maryland School of Medicine’s Center for Vaccine Development announced on Thursday that it has received a renewed contract from the National Institute of Allergy and Infectious Diseases for its research and clinical studies.
“The University of Maryland’s Center for Vaccine Development has long been a partner of the federal government in the clinical evaluation of vaccines,” Karen L. Kotloff, a professor of pediatrics and medicine and the head of infectious disease and tropical pediatrics at the University of Maryland’s School of Medicine, said. “Renewal of our contract is a testimony to our expertise in helping protect people throughout the world against diseases that pose significant public health threats.”
After nearly 17 years, Elaine Amir, executive director of Johns Hopkins University Montgomery County Campus, retired, effective Sept. 30. Elaine has been the face of Johns Hopkins in Montgomery County and a leader on several community boards and initiatives. Through her work, she touched many lives, both personally and professionally.
Before she left, Hopkins Happenings asked her to look back on her years leading JHU MCC:
Donald E. Ingber, a professor at Harvard University, has combined advanced electronics and biology to create a “lung on a chip,” a breakthrough device that could safely allow precise tests of risky new medical treatments before they are tried out on humans.
Just as eye-opening as his work, however, may be his source of federal financing.
It’s not the National Institutes of Health, the $30-billion agency that is the largest provider of federal basic-research money to universities. Instead it’s the Defense Advanced Research Projects Agency, or Darpa, an agency one-tenth as large as NIH and responsible primarily for meeting the military’s technological needs.
Cydan, LLC, an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential, today announced that the company has expanded its initial round of financing, bringing its total financing raised to $26 million. Cydan launched in April 2013 with a $16 million financing from New Enterprise Associates (NEA), Pfizer Venture Investments and Alexandria Venture Investments. New investors Lundbeckfond Ventures and Bay City Capital led the $10 million expansion of this round of financing and were joined by Cydan’s previous investors NEA and Alexandria Venture Investments. In conjunction with this investment, Lundbeckfond Ventures Managing Partner Mette Kirstine Agger, MBA and Bay City Capital Investment Partner and Managing Director Carl Goldfischer, M.D., are joining Cydan’s Board of Directors.
Sequencing the human genome seemed like a discovery so important that it couldn’t be overhyped—we had, after all, transcribed the blueprint for human life—but biotech executives somehow managed the trick. William Haseltine, the founder of Human Genome Sciences, predicted in 2000 that he would halve the time and money required to bring a drug to market. Randy Scott of Incyte Genomics claimed that, “In 10 years, we will understand the molecular basis for most human diseases.”
Not quite. The cost of bringing a drug to market has increased dramatically, quibbles about accounting methods notwithstanding. The process still takes more than a decade. We already had a thorough understanding of diseases linked to single genetic sequences, such as Huntington’s and cystic fibrosis, but if anything, exploring the genome has taught us how complicated the relationship between genes and diseases really is. Last year, for example, researchers in Canada linked 71 genetic regions to inflammatory bowel disease, bringing the total to 163 and counting.
An early-stage investment fund founded by Revolution has raised $200 million in commitments, blowing past its $150 million goal. The new fund, Revolution Ventures, will invest in technology firms, mostly under $10 million in revenue, that are seeking to disrupt traditional industries.
“We are doing the things that we’ve been doing for the last decade,” Revolution co-founder Steve Case said. “Trying to find early-stage companies that are using technology to disrupt traditional industries, create new business models and have all kinds of different aspects that we find interesting.”
Two days into a government shutdown over resulting from the Congressional showdown over funding Obamacare, funding is at the front of mind for many researchers who rely at least partially on grants from National Institutes of Health and other government sources. A survey of 608 translational researchers revealed that although insufficient funding is a significant barrier to the path to commercializing their work, there are other related challenges that are just as critical to their future.
How can translational researchers improve the rate of reproducible results? What other factors are undercutting funding? Where can they find collaboration opportunities?
The STEM workforce in the DC area is sizable and totals about 330,000 workers. Some of these employees are retiring, some are changing jobs, and others are getting promotions leaving positions open. The healthy STEM climate means that there are a lot of job opportunities at all levels. But where do your students find STEM jobs? On TCM’s targeted career center, CORE.
CORE is a comprehensive resource for finding all levels of biotechnology, technology, and business jobs in the Mid-Atlantic region.CORE provides detailed job and internship listings in 15 categories that are updated frequently and promoted through our social media channels for easy access. Many companies in the area that hire STEM workers are TCM members and are vested in hiring local talent. So prepare your students for success and direct them to CORE. In addition to job listings, we also offer timely career resource articles to help students meet the many challenges of their job search.
Want to show your students that you’re committed to their future? Purchase a banner ad on the CORE website to let local companies know about the courses, certificates, and degrees you offer to prepare your students for STEM jobs.
Even people without diabetes could be at higher risk of dying from disease
High blood sugar has been linked to a greater risk of dying from several types of cancer, a potentially worrying finding for countries with growing rates of obesity.
Researchers from Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland, USA and Yonsei University in Seoul, Korea made the discovery by following more than 1.2 million Koreans for 10 years.
A veteran biotechnology reporter once complained privately that covering the industry was like watching grass grow—companies seemed to inch by slow degrees toward products and profits, sustained by a dwindling stream of funding.
For an antidote to that dreary picture, consider the swift developments at StartX Med, a life sciences accelerator program founded by Stanford University students in 2012. It’s a health care-oriented offshoot of StartX, the original student-initiated incubator program for researchers and others affiliated with Stanford.
BIO’s announced agreement with National Science Foundation (NSF) to bring SBIR-funded, early-stage biotech companies to present at BIO Investor Forum 2013. Presenting companies in NSF track include ADMdx, Biodesy, Carmot, CertiChem, Jade Therapeutics, Nano3D Biosciences, Nanofiber Solutions, Parabon Nanolabs, Stemina, and Tymora Analytical Operations. All are funded by NSF and focused on drug discovery, diagnostics, and other platform technologies.
When Sunnyvale, Calif.-based Intuitive Surgical hit the market in 1999 with its surgical robot, da Vinci, the company and many of its early adopters hailed the new technology as a revolution that would benefit patients, surgeons and the health care system as a whole. Da Vinci combines high-definition visual tools with robot-guided medical instruments that allow surgeons to do complicated procedures using a few tiny incisions. The da Vinci system, which is widely used in urologic surgeries such as the removal of prostate tumors, has been shown by Intuitive and outside researchers to reduce post-surgery complications and shorten hospital stays.
The Department of Health and Human Services isn’t the only federal agency interested in funding medical research.
Defense Advanced Research Projects Agency, the Department of Defense’s primary innovation engine that’s responsible for developing new technologies for use by the military, also frequently undertakes project in biology, medicine and neuroscience.
Improving health literacy and patient engagement and developing alternative ways to appraise apps and physicians are among the ideas that have reached the finals of a Robert Wood Johnson Foundation competition. The people and companies behind these ideas are vying for the opportunity to get funding as part of a program to fund transformative innovations in healthcare.
Among the judges are Angel investor Esther Dyson (@edyson), PatientsLikeMe Co-Founder and President Ben Heywood (@patientslikeme), Rhode Island School of Design President John Maeda(@johnmaeda), IDEO Life Sciences Chief Strategist Rodrigo Martinez(@rodrigoatcg), Games for Health Co-Founder Ben Sawyer (@bensawyer), Fast Company Staff Writer Ben Schiller(@btschiller) and NPR Science Correspondent Shankar Vedantam(@hiddenbrain).
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
With Fall approaching, everyone is preparing for their favorite things whether that’s football season, pumpkin carving, or more reasonable temperatures in Central Maryland. Fall is also a great time for the Small Business Innovation Research grant program throughout National Institutes of Health. In partnership with the NIH, BioHealth Innovation is sponsoring a fall gathering to talk about SBIR awards.
